{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:55Z","timestamp":1793137015516,"version":"4.5.0"},"reference-count":90,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0196","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:22:24Z","timestamp":1732090944000},"source":"Crossref","is-referenced-by-count":9,"title":["The diagnosis and treatment of hypertrophic cardiomyopathy"],"prefix":"10.3238","author":[{"given":"Maximilian N.","family":"M\u00f6bius-Winkler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Lenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"10.3238\/arztebl.m2024.0196_ref1","doi-asserted-by":"crossref","unstructured":"Maron BJ, Epstein SE: Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979; 43: 1242\u20134","DOI":"10.1016\/0002-9149(79)90160-7"},{"key":"10.3238\/arztebl.m2024.0196_ref2","doi-asserted-by":"crossref","unstructured":"Members WC, Ommen SR, Mital S, et al.: 2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circ 2020; 142: e558\u2013e631","DOI":"10.1161\/CIR.0000000000000945"},{"key":"10.3238\/arztebl.m2024.0196_ref3","doi-asserted-by":"crossref","unstructured":"Hughes RK, Knott KD, Malcolmson J, et al.: Apical hypertrophic cardiomyopathy: The variant less known. J Am Heart Assoc, 2020; 9: e015294","DOI":"10.1161\/JAHA.119.015294"},{"key":"10.3238\/arztebl.m2024.0196_ref4","doi-asserted-by":"crossref","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al.: 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44: 3503\u2013626","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"10.3238\/arztebl.m2024.0196_ref5","doi-asserted-by":"crossref","unstructured":"Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO: Sudden deaths in young competitive athletes analysis of 1866 deaths in the United States, 1980\u20132006. Circ 2009; 119: 1085\u201392","DOI":"10.1161\/CIRCULATIONAHA.108.804617"},{"key":"10.3238\/arztebl.m2024.0196_ref6","doi-asserted-by":"crossref","unstructured":"Harris KM, Spirito P, Maron MS, et al.: Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114: 216\u201325","DOI":"10.1161\/CIRCULATIONAHA.105.583500"},{"key":"10.3238\/arztebl.m2024.0196_ref7","doi-asserted-by":"crossref","unstructured":"Hebl VB, Miranda WR, Ong KC, et al.: The natural history of nonobstructive hypertrophic cardiomyopathy. Mayo Clin Proc 2016; 91: 279\u201387","DOI":"10.1016\/j.mayocp.2016.01.002"},{"key":"10.3238\/arztebl.m2024.0196_ref8","doi-asserted-by":"crossref","unstructured":"Elliott PM, Gimeno JR, Thaman R, et al.: Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006; 92: 785\u201391","DOI":"10.1136\/hrt.2005.068577"},{"key":"10.3238\/arztebl.m2024.0196_ref9","doi-asserted-by":"crossref","unstructured":"Hartmannova H, Kubanek M, Sramko M, et al.: Isolated X-linked hypertrophic cardiomyopathy caused by a novel mutation of the four-and-a-half LIM domain 1 gene. Circ Cardiovasc Genet 2013; 6: 543\u201351","DOI":"10.1161\/CIRCGENETICS.113.000245"},{"key":"10.3238\/arztebl.m2024.0196_ref10","doi-asserted-by":"crossref","unstructured":"Branzi A, Romeo G, Specchia S, et al.: Genetic heterogeneity of hypertrophic cardiomyopathy. Int J Cardiol 1985; 7: 129\u201338","DOI":"10.1016\/0167-5273(85)90352-3"},{"key":"10.3238\/arztebl.m2024.0196_ref11","doi-asserted-by":"crossref","unstructured":"Maron BJ: Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018; 379: 655\u201368","DOI":"10.1056\/NEJMra1710575"},{"key":"10.3238\/arztebl.m2024.0196_ref12","doi-asserted-by":"crossref","unstructured":"Millat G, Bouvagnet P, Chevalier P, et al.: Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet 2010; 53: 261\u20137","DOI":"10.1016\/j.ejmg.2010.07.007"},{"key":"10.3238\/arztebl.m2024.0196_ref13","doi-asserted-by":"crossref","unstructured":"Walsh R, Buchan R, Wilk A, et al.: Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J 2017; 38: 3461\u20138","DOI":"10.1093\/eurheartj\/ehw603"},{"key":"10.3238\/arztebl.m2024.0196_ref14","doi-asserted-by":"crossref","unstructured":"Richard P, Charron P, Carrier L, et al.: Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circ 2003; 107: 2227\u201332","DOI":"10.1161\/01.CIR.0000066323.15244.54"},{"key":"10.3238\/arztebl.m2024.0196_ref15","doi-asserted-by":"crossref","unstructured":"Maron BJ, Ferrans VJ, Henry WL, et al.: Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH). Light and electron microscopic findings. Circ 1974; 50: 436\u201346","DOI":"10.1161\/01.CIR.50.3.436"},{"key":"10.3238\/arztebl.m2024.0196_ref16","doi-asserted-by":"crossref","unstructured":"Ohsato K, Shimizu M, Sugihara N, Konjshi K, Takeda R: Histopathological factors related to diastolic function in myocardial hypertrophy. Jpn Circ J 1992; 56: 325\u201333","DOI":"10.1253\/jcj.56.325"},{"key":"10.3238\/arztebl.m2024.0196_ref17","doi-asserted-by":"crossref","unstructured":"Cannon RO, Rosing DR, Maron BJ, et al.: Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circ 1985; 71: 234\u201343","DOI":"10.1161\/01.CIR.71.2.234"},{"key":"10.3238\/arztebl.m2024.0196_ref18","doi-asserted-by":"crossref","unstructured":"Maron BJ, Wolfson JK, Epstein SE, Roberts WC: Intramural (\u201csmall vessel\u201d) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8: 545\u201357","DOI":"10.1016\/S0735-1097(86)80181-4"},{"key":"10.3238\/arztebl.m2024.0196_ref19","doi-asserted-by":"crossref","unstructured":"Raphael CE, Cooper R, Parker KH, et al.: Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. J Am Coll Cardiol 2016; 68: 1651\u201360","DOI":"10.1016\/j.jacc.2016.07.751"},{"key":"10.3238\/arztebl.m2024.0196_ref20","doi-asserted-by":"crossref","unstructured":"Maron MS, Olivotto I, Harrigan C, et al.: Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011; 124: 40\u20137","DOI":"10.1161\/CIRCULATIONAHA.110.985812"},{"key":"10.3238\/arztebl.m2024.0196_ref21","doi-asserted-by":"crossref","unstructured":"Kim DH, Handschumacher MD, Levine RA, et al.: In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction. Circulation 2010; 122: 1298\u2013307","DOI":"10.1161\/CIRCULATIONAHA.109.935551"},{"key":"10.3238\/arztebl.m2024.0196_ref22","doi-asserted-by":"crossref","unstructured":"Palyam V, Azam AT, Odeyinka O, et al.: Hypertrophic cardiomyopathy and atrial fibrillation: a review. Cureus 2022; 14: e21101","DOI":"10.7759\/cureus.21101"},{"key":"10.3238\/arztebl.m2024.0196_ref23","doi-asserted-by":"crossref","unstructured":"Frenneaux MP, Counihan PJ, Caforio ALP, Chikamori T, McKenna WJ: Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990; 82: 1995\u20132002","DOI":"10.1161\/01.CIR.82.6.1995"},{"key":"10.3238\/arztebl.m2024.0196_ref24","doi-asserted-by":"crossref","unstructured":"Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F: Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 2044\u201351","DOI":"10.1016\/S0735-1097(99)00094-7"},{"key":"10.3238\/arztebl.m2024.0196_ref25","doi-asserted-by":"crossref","unstructured":"Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ: Hypertrophic cardiomyopathy in tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26: 1529\u201336","DOI":"10.1016\/0735-1097(95)00353-3"},{"key":"10.3238\/arztebl.m2024.0196_ref26","doi-asserted-by":"crossref","unstructured":"Cannan CR, Reeder GS, Bailey KR, Melton LJ, Gersh BJ: Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation 1995; 92: 2488\u201395","DOI":"10.1161\/01.CIR.92.9.2488"},{"key":"10.3238\/arztebl.m2024.0196_ref27","doi-asserted-by":"crossref","unstructured":"Kubo T, Kitaoka H, Okawa M, et al.: Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy\u2014results from Kochi RYOMA study. Circ J 2009; 73: 1599\u2013605","DOI":"10.1253\/circj.CJ-09-0140"},{"key":"10.3238\/arztebl.m2024.0196_ref28","doi-asserted-by":"crossref","unstructured":"Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ: Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993; 72: 939\u201343","DOI":"10.1016\/0002-9149(93)91111-T"},{"key":"10.3238\/arztebl.m2024.0196_ref29","doi-asserted-by":"crossref","unstructured":"Elliott PM, Anastasakis A, Borger MA, et al.: 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC). Eur Heart J 2014; 35: 2733\u201379","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"10.3238\/arztebl.m2024.0196_ref30","doi-asserted-by":"crossref","unstructured":"Savage DD, Seides SF, Clark CE, et al.: Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circ 1978; 58: 402\u20138","DOI":"10.1161\/01.CIR.58.3.402"},{"key":"10.3238\/arztebl.m2024.0196_ref31","doi-asserted-by":"crossref","unstructured":"McLeod CJ, Ackerman MJ, Nishimura RA, Tajik AJ, Gersh BJ, Ommen SR: Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol 2009; 54: 229\u201333","DOI":"10.1016\/j.jacc.2009.02.071"},{"key":"10.3238\/arztebl.m2024.0196_ref32","doi-asserted-by":"crossref","unstructured":"Ommen SR, Ho CY, Asif IM, et al.: 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the american heart association\/american college of cardiology joint committee on clinical practice guidelines. Circulation 2024; 149: e1239\u2013311","DOI":"10.1161\/CIR.0000000000001250"},{"key":"10.3238\/arztebl.m2024.0196_ref33","doi-asserted-by":"crossref","unstructured":"Amano Y, Kitamura M, Takano H, et al.: Cardiac MR imaging of hypertrophic cardiomyopathy: techniques, findings, and clinical relevance. Magn Reson Med Sci 2018; 17: 120\u2013131","DOI":"10.2463\/mrms.rev.2017-0145"},{"key":"10.3238\/arztebl.m2024.0196_ref34","doi-asserted-by":"crossref","unstructured":"Wigle ED, Sasson Z, Henderson MA, et al.: Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985; 28: 1\u201383","DOI":"10.1016\/0033-0620(85)90024-6"},{"key":"10.3238\/arztebl.m2024.0196_ref35","doi-asserted-by":"crossref","unstructured":"van der Wall EE: New ESC guidelines on hypertrophic cardiomyopathy: new insights in invasive treatment? Neth Heart J 2015 Jan; 23: 1\u20133","DOI":"10.1007\/s12471-014-0636-7"},{"key":"10.3238\/arztebl.m2024.0196_ref36","doi-asserted-by":"crossref","unstructured":"Saberi S, Wheeler M, Bragg-Gresham J, et al.: Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy a randomized clinical trial. JAMA 2017; 317: 1349\u201357","DOI":"10.1001\/jama.2017.2503"},{"key":"10.3238\/arztebl.m2024.0196_ref37","doi-asserted-by":"crossref","unstructured":"Klempfner R, Kamerman T, Schwammenthal E, et al.: Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center. Eur J Prev Cardiol 2015; 22: 13\u20139","DOI":"10.1177\/2047487313501277"},{"key":"10.3238\/arztebl.m2024.0196_ref38","doi-asserted-by":"crossref","unstructured":"Kwon S, Lee HJ, Han K Do, et al.: Association of physical activity with all-cause and cardiovascular mortality in 7666 adults with hypertrophic cardiomyopathy (HCM): more physical activity is better. Br J Sports Med 2021; 55: 1034\u201340","DOI":"10.1136\/bjsports-2020-101987"},{"key":"10.3238\/arztebl.m2024.0196_ref39","doi-asserted-by":"crossref","unstructured":"Maron BJ, Casey SA, Olivotto I, et al.: Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2018; 11: e005820","DOI":"10.1161\/CIRCEP.117.005820"},{"key":"10.3238\/arztebl.m2024.0196_ref40","doi-asserted-by":"crossref","unstructured":"Toshima H, Koga Y, Nagata H, Toyomasu K, Itaya KI, Matoba T: Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy double-blind crossover study. Jpn Heart J 1986; 27: 701\u201315","DOI":"10.1536\/ihj.27.701"},{"key":"10.3238\/arztebl.m2024.0196_ref41","doi-asserted-by":"crossref","unstructured":"Alfares AA, Kelly MA, McDermott G, et al.: Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med 2015; 17: 880\u20138","DOI":"10.1038\/gim.2014.205"},{"key":"10.3238\/arztebl.m2024.0196_ref42","doi-asserted-by":"crossref","unstructured":"Marian AJ: The case of \u2018missing causal genes\u2019 and the practice of medicine. A Sherlock Holmes approach of deductive reasoning. Circ Res 2016; 119: 21\u20134","DOI":"10.1161\/CIRCRESAHA.116.308830"},{"key":"10.3238\/arztebl.m2024.0196_ref43","doi-asserted-by":"crossref","unstructured":"Maron MS, Olivotto I, Zenovich AG, et al.: Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114: 2232\u20139","DOI":"10.1161\/CIRCULATIONAHA.106.644682"},{"key":"10.3238\/arztebl.m2024.0196_ref44","doi-asserted-by":"crossref","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE: Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation 1995; 92: 785\u20139","DOI":"10.1161\/01.CIR.92.4.785"},{"key":"10.3238\/arztebl.m2024.0196_ref45","doi-asserted-by":"crossref","unstructured":"Maron BJ, Spirito P, Roman MJ, et al.: Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the strong heart study). Am J Cardiol 2004; 93: 1510\u20134","DOI":"10.1016\/j.amjcard.2004.03.007"},{"key":"10.3238\/arztebl.m2024.0196_ref46","doi-asserted-by":"crossref","unstructured":"Hada Y, Sakamoto T, Amano K, et al.: Prevalence of hypertrophic cardiomyopathy in a population of adult japanese workers as detected by echocardiographic screening. Am J Cardiol 1987; 59: 183\u20134","DOI":"10.1016\/S0002-9149(87)80107-8"},{"key":"10.3238\/arztebl.m2024.0196_ref47","doi-asserted-by":"crossref","unstructured":"Zou Y, Song L, Wang Z, et al.: Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 2004; 116: 14\u20138","DOI":"10.1016\/j.amjmed.2003.05.009"},{"key":"10.3238\/arztebl.m2024.0196_ref48","unstructured":"Statistisches Bundesamt: Bev\u00f6lkerung nach Nationalit\u00e4t und Geschlecht (Quartalszahlen). www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/liste-zensus-geschlecht-staatsangehoerigkeit.html#616584 (last accessed on 1 July 2023)."},{"key":"10.3238\/arztebl.m2024.0196_ref49","doi-asserted-by":"crossref","unstructured":"Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M: Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes 2020; 4: 102","DOI":"10.1186\/s41687-020-00269-8"},{"key":"10.3238\/arztebl.m2024.0196_ref50","doi-asserted-by":"crossref","unstructured":"Kubo T, Kitaoka H, Okawa M, et al.: Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy\u2014results from Kochi RYOMA study. Circ J 2009; 73: 1599\u2013605.","DOI":"10.1253\/circj.CJ-09-0140"},{"key":"10.3238\/arztebl.m2024.0196_ref51","doi-asserted-by":"crossref","unstructured":"Cannan CR, Reeder GS, Bailey KR, Melton LJ, Gersh BJ: Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circ 1995; 92: 2488\u201395","DOI":"10.1161\/01.CIR.92.9.2488"},{"key":"10.3238\/arztebl.m2024.0196_ref52","doi-asserted-by":"crossref","unstructured":"Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ: Hypertrophic cardiomyopathy in tuscany: clinical course and outcome in an unselected regional population. Am Coll Cardiol 1995; 26: 1529\u201336","DOI":"10.1016\/0735-1097(95)00353-3"},{"key":"10.3238\/arztebl.m2024.0196_ref53","doi-asserted-by":"crossref","unstructured":"Maron BJ, Desai MY, Nishimura RA, et al.: Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022; 79: 372\u201389","DOI":"10.1016\/j.jacc.2021.12.002"},{"key":"10.3238\/arztebl.m2024.0196_ref54","doi-asserted-by":"crossref","unstructured":"Rodrigues JCL, Rohan S, Ghosh Dastidar A, et al.: Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥\u00a015 mm. Eur Radiol 2017; 27: 1125\u201335","DOI":"10.1007\/s00330-016-4468-2"},{"key":"10.3238\/arztebl.m2024.0196_ref55","doi-asserted-by":"crossref","unstructured":"M\u00e9ndez C, Soler R, Rodr\u00edguez E, Barriales R, Ochoa JP, Monserrat L: Differential diagnosis of thickened myocardium: an illustrative MRI review. Insights Imaging 2018; 9: 695\u2013707","DOI":"10.1007\/s13244-018-0655-9"},{"key":"10.3238\/arztebl.m2024.0196_ref56","doi-asserted-by":"crossref","unstructured":"Syed IS, Glockner JF, Feng DL, et al.: Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3: 155\u201364","DOI":"10.1016\/j.jcmg.2009.09.023"},{"key":"10.3238\/arztebl.m2024.0196_ref57","doi-asserted-by":"crossref","unstructured":"Witteles RM, Bokhari S, Damy T, et al.: Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 2019; 7: 709\u2013716","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"10.3238\/arztebl.m2024.0196_ref58","doi-asserted-by":"crossref","unstructured":"Petersen SE, Selvanayagam JB, Francis JM, et al.: Differentiation of athlete\u2019s heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2005; 7: 551\u20138","DOI":"10.1081\/JCMR-200060631"},{"key":"10.3238\/arztebl.m2024.0196_ref59","doi-asserted-by":"crossref","unstructured":"Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P: The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991; 324: 295\u2013301","DOI":"10.1056\/NEJM199101313240504"},{"key":"10.3238\/arztebl.m2024.0196_ref60","doi-asserted-by":"crossref","unstructured":"Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F: Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 2002; 105: 944\u20139","DOI":"10.1161\/hc0802.104534"},{"key":"10.3238\/arztebl.m2024.0196_ref61","doi-asserted-by":"crossref","unstructured":"Pelliccia A, Maron MS, Maron BJ: Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete\u2019s heart from pathologic hypertrophy. Prog Cardiovasc Dis 2012; 54: 387\u201396","DOI":"10.1016\/j.pcad.2012.01.003"},{"key":"10.3238\/arztebl.m2024.0196_ref62","doi-asserted-by":"crossref","unstructured":"Mathias IS, Oliveira Lima Filho JO, Culver DA, et al.: Case report of isolated cardiac sarcoidosis presenting as hypertrophic obstructive cardiomyopathy\u2014a clinical picture printed on lenticular paper. Eur Heart J Case Rep 2021; 26; 5: ytab208","DOI":"10.1093\/ehjcr\/ytab208"},{"key":"10.3238\/arztebl.m2024.0196_ref63","doi-asserted-by":"crossref","unstructured":"Ueberham L, Hagendorff A, Klingel K, et al.: Pathophysiological gaps, diagnostic challenges, and uncertainties in cardiac sarcoidosis. J Am Heart Assoc. 2023; 12: e027971","DOI":"10.1161\/JAHA.122.027971"},{"key":"10.3238\/arztebl.m2024.0196_ref64","doi-asserted-by":"crossref","unstructured":"Ueberham L, Paetsch I, Jahnke C, Klingel K, Dinov B: Right ventricular thickening and extensive late gadolinium enhancement in a patient with rare case of isolated cardiac sarcoidosis and initially negative biopsy. Eur Heart J Cardiovasc Imaging 2017; 18: 1427\u20138","DOI":"10.1093\/ehjci\/jex226"},{"key":"10.3238\/arztebl.m2024.0196_ref65","doi-asserted-by":"crossref","unstructured":"Ruiz-Guerrero L, Barriales-Villa R: Storage diseases with hypertrophic cardiomyopathy phenotype. Glob Cardiol Sci Pract 2018; 2018: 28","DOI":"10.21542\/gcsp.2018.28"},{"key":"10.3238\/arztebl.m2024.0196_ref66","doi-asserted-by":"crossref","unstructured":"Arad M, Maron BJ, Gorham JM, et al.: Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352: 362\u201372","DOI":"10.1056\/NEJMoa033349"},{"key":"10.3238\/arztebl.m2024.0196_ref67","doi-asserted-by":"crossref","unstructured":"Spirito P, Bellone P, Harris KM, Bernab\u00f2 P, Bruzzi P, Maron BJ: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778\u201385","DOI":"10.1056\/NEJM200006153422403"},{"key":"10.3238\/arztebl.m2024.0196_ref68","doi-asserted-by":"crossref","unstructured":"O\u2019Mahony C, Jichi F, Pavlou M, et al.: A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014; 35: 2010\u201320","DOI":"10.1093\/eurheartj\/eht439"},{"key":"10.3238\/arztebl.m2024.0196_ref69","doi-asserted-by":"crossref","unstructured":"Spirito P, Autore C, Rapezzi C, et al.: Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009; 119: 1703\u201310","DOI":"10.1161\/CIRCULATIONAHA.108.798314"},{"key":"10.3238\/arztebl.m2024.0196_ref70","doi-asserted-by":"crossref","unstructured":"Rowin EJ, Maron BJ, Carrick RT, et al.: Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J Am Coll Cardiol 2020; 75: 3033\u201343","DOI":"10.1016\/j.jacc.2020.04.045"},{"key":"10.3238\/arztebl.m2024.0196_ref71","doi-asserted-by":"crossref","unstructured":"Rowin EJ, Maron BJ, Haas TS, et al.: Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol 2017; 69: 761\u201373","DOI":"10.1016\/j.jacc.2016.11.063"},{"key":"10.3238\/arztebl.m2024.0196_ref72","doi-asserted-by":"crossref","unstructured":"Mentias A, Raeisi-Giglou P, Smedira NG, et al.: Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol 2018; 72: 857\u201370","DOI":"10.1016\/j.jacc.2018.05.060"},{"key":"10.3238\/arztebl.m2024.0196_ref73","doi-asserted-by":"crossref","unstructured":"Weng Z, Yao J, Chan RH, et al.: Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 2016; 9: 1392\u2013402","DOI":"10.1016\/j.jcmg.2016.02.031"},{"key":"10.3238\/arztebl.m2024.0196_ref74","doi-asserted-by":"crossref","unstructured":"Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ: Non- sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873\u20139","DOI":"10.1016\/S0735-1097(03)00827-1"},{"key":"10.3238\/arztebl.m2024.0196_ref75","doi-asserted-by":"crossref","unstructured":"Olivotto I, Maron MS, Adabag AS, et al.: Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 480\u20137","DOI":"10.1016\/j.jacc.2005.04.043"},{"key":"10.3238\/arztebl.m2024.0196_ref76","doi-asserted-by":"crossref","unstructured":"Elliott PM, Gimeno JR, Tom\u00e9 MT, et al.: Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27: 1933\u201341","DOI":"10.1093\/eurheartj\/ehl041"},{"key":"10.3238\/arztebl.m2024.0196_ref77","doi-asserted-by":"crossref","unstructured":"Frank MJ, Abdulla AM, Watkins LO, Prisant L, Stefadouros MA: Long-term medical management of hypertrophic cardiomyopathy: usefulness of propranolol. Eur Heart J 1983; 4: 155\u201364","DOI":"10.1093\/eurheartj\/4.suppl_F.155"},{"key":"10.3238\/arztebl.m2024.0196_ref78","doi-asserted-by":"crossref","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH: Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021; 78: 2505\u201317","DOI":"10.1016\/j.jacc.2021.07.065"},{"key":"10.3238\/arztebl.m2024.0196_ref79","doi-asserted-by":"crossref","unstructured":"Rosing DR, Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4 U, Maron BJ, Bonow RO, Epstein SE: Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985; 55: 185B-95B","DOI":"10.1016\/0002-9149(85)90630-7"},{"key":"10.3238\/arztebl.m2024.0196_ref80","doi-asserted-by":"crossref","unstructured":"Paz R, Jortner R, Tunick PA, et al.: The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy. N Engl J Med 1996; 335: 938\u201341","DOI":"10.1056\/NEJM199609263351305"},{"key":"10.3238\/arztebl.m2024.0196_ref81","doi-asserted-by":"crossref","unstructured":"Green EM, Wakimoto H, Anderson RL, et al.: Heart disease: a small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016; 351: 617\u201321","DOI":"10.1126\/science.aad3456"},{"key":"10.3238\/arztebl.m2024.0196_ref82","doi-asserted-by":"crossref","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al.: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet 2020; 396: 759\u201369","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"10.3238\/arztebl.m2024.0196_ref83","unstructured":"FDA center for drug evaluation and research. Mavacamten (Camzyos). Clinical and statistical reviews application number.www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214998Orig1s000Med_StatR.pdf (last accessed on 22 October 2024)."},{"key":"10.3238\/arztebl.m2024.0196_ref84","unstructured":"Bundesministerium f\u00fcr Gesundheit: Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie: Anlage XII\u2014Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a des F\u00fcnften Buches Sozialgesetzbuch (SGB V)\u2014Mavacamten (Symptomatische hypertrophe obstruktive Kardiomyopathie (NYHA Klasse II\u2013III)) vom: 01.02.2024. BAnz AT 28.02.2024 B4. 2024. www.bundesanzeiger.de\/pub\/de\/amtliche-veroeffentlichung?1 (last accessed on 30 June 2024)."},{"key":"10.3238\/arztebl.m2024.0196_ref85","doi-asserted-by":"crossref","unstructured":"Iacovoni A, Spirito P, Simon C, et al.: A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J 2012; 33: 2080\u20137","DOI":"10.1093\/eurheartj\/ehs064"},{"key":"10.3238\/arztebl.m2024.0196_ref86","doi-asserted-by":"crossref","unstructured":"Kotkar KD, Said SM, Dearani JA, Schaff H V.: Hypertrophic obstructive cardiomyopathy: the mayo clinic experience. Ann Cardiothorac Surg 2017; 6: 329\u201336","DOI":"10.21037\/acs.2017.07.03"},{"key":"10.3238\/arztebl.m2024.0196_ref87","doi-asserted-by":"crossref","unstructured":"Ommen SR, Maron BJ, Olivotto I, et al.: Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 470\u20136.","DOI":"10.1016\/j.jacc.2005.02.090"},{"key":"10.3238\/arztebl.m2024.0196_ref88","doi-asserted-by":"crossref","unstructured":"Desai MY, Bhonsale A, Smedira NG, et al.: Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation 2013; 128: 209\u201316","DOI":"10.1161\/CIRCULATIONAHA.112.000849"},{"key":"10.3238\/arztebl.m2024.0196_ref89","doi-asserted-by":"crossref","unstructured":"Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211\u20134","DOI":"10.1016\/S0140-6736(95)91267-3"},{"key":"10.3238\/arztebl.m2024.0196_ref90","doi-asserted-by":"crossref","unstructured":"Osman M, Kheiri B, Osman K, et al.: Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: systematic review and meta-analysis. Clin Cardiol. 2019; 42: 190\u20137","DOI":"10.1002\/clc.23113"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:44:46Z","timestamp":1732243486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":90,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0196","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}